Featured Research

from universities, journals, and other organizations

Tailor-made molecule to work against malaria

Date:
March 12, 2014
Source:
Université de Genève
Summary:
The malaria parasite is particularly pernicious since it is built to develop resistance to treatments. The lack of new therapeutic approaches also contributes to the persistence of this global scourge. A new study describes a new class of molecules targeting the two problems at the same time.

This is a modeled representation of an inhibitory molecule (yellow) in a "pocket" of the HSP90 protein of the parasite (pink).
Credit: Tai Wang, University of Geneva

The malaria parasite is particularly pernicious since it is built to develop resistance to treatments. The lack of new therapeutic approaches also contributes to the persistence of this global scourge.

Related Articles


A study led by Didier Picard, professor at the Faculty of Sciences of the University of Geneva (UNIGE), Switzerland, describes a new class of molecules targeting the two problems at the same time. Using ultra sophisticated computerized modelling tools, the researchers were successful in identifying a type of candidate molecules toxic for the pathogen, but not for the infected human red blood cells. The study, led in collaboration with researchers from the Geneva-Lausanne School of Pharmacy (EPGL) and the University of Basel, has been published in the Journal of Medicinal Chemistry.

The most severe form of malaria is caused by infection with Plasmodium falciparum. The eradication of this parasite is even more difficult as it becomes resistant to treatments. The group led by Didier Picard, professor of biology at the Faculty of Sciences of UNIGE, Switzerland, is closely interested in the protein Heat Shock Protein 90 (HSP90), which plays a central role for several factors involved in the life cycle, survival and resistance of the pathogen.

Modelling the target-protein of the Plasmodium

Expressed in organisms as diverse as bacteria and mammal cells, HSP90 acts as a "chaperone," by helping other proteins during both normal and stressful periods. In the Plasmodium, HSP90 protects parasitic proteins during high fevers triggered by its presence. The chaperone also participates in the maturation of the pathogen in human red blood cells. "Our goal was to determine if there was a difference between the human form and the parasitic form of HSP90 that we could exploit for therapeutic purposes," explains Tai Wang, a PhD student at the Department of Cell Biology of UNIGE.

The PhD student used ultra-sophisticated computerized modelling tools to characterize the various tridimensional conformations of the parasite's HSP90. "The human chaperone harbors a "pocket" that binds molecules known to inhibit its activity. I compared it with that of the Plasmodium, hoping to find a difference which could be targeted by a specific inhibitor, but didn't," reported the researcher.

A screening performed entirely in silico

By studying the HSP90 of the pathogen from every possible angle, Tai Wang discovered another pocket capable of binding inhibitory substances, completely absent in its human alter ego. Using a supercomputer, he performed the screening of a virtual library containing more than a million chemical compounds while retaining those that could fit in this pocket. This screening in silico led him to select five candidates.

These experiments were then completed by a "real time" modelling technique. "The simulations were conducted to analyze the dynamics of interaction between the HSP90 and the candidates, leading to the discovery of inhibitors which interact specifically with the Plasmodium falciparum chaperone."

The molecules were then tested in vitro in different systems. The biologists demonstrated in particular the toxicity of those inhibitors on Plasmodium falciparum cultures, in doses sufficient to kill the parasites without affecting the infected red blood cells.

"These recently patented molecules are part of a group of compounds related to the 7-azaindoles, which exclusively bind the HSP90 of the parasite, but not the human form. The next step will be to fine-tune them in order to perform clinical tests," concluded Didier Picard.


Story Source:

The above story is based on materials provided by Université de Genève. Note: Materials may be edited for content and length.


Journal Reference:

  1. Tai Wang, William H. Bisson, Pascal Mäser, Leonardo Scapozza, Didier Picard. Differences in Conformational Dynamics betweenPlasmodium falciparumand Human Hsp90 Orthologues Enable the Structure-Based Discovery of Pathogen-Selective Inhibitors. Journal of Medicinal Chemistry, 2014; 140303072024000 DOI: 10.1021/jm401801t

Cite This Page:

Université de Genève. "Tailor-made molecule to work against malaria." ScienceDaily. ScienceDaily, 12 March 2014. <www.sciencedaily.com/releases/2014/03/140312082747.htm>.
Université de Genève. (2014, March 12). Tailor-made molecule to work against malaria. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2014/03/140312082747.htm
Université de Genève. "Tailor-made molecule to work against malaria." ScienceDaily. www.sciencedaily.com/releases/2014/03/140312082747.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) — The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) — An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins